Legal & General Group
RGC icon

Legal & General Group’s Regencell Bioscience RGC Stock Holding History

Legal & General Group’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Buy
+9,903
New +$280K ﹤0.01% 2498

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Legal & General Group's RGC Position: Q1 2026 in Review

Legal & General Group opened a new position in Regencell Bioscience (RGC) in Q1 2026: 9,903 shares worth $252K. The stake represents ﹤0.01% of the portfolio and ranks #2498 among its holdings.

31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Legal & General Group held 9,903 shares of Regencell Bioscience worth $252K as of Q1 2026.
  • Regencell Bioscience was a new Legal & General Group position in Q1 2026.
  • Regencell Bioscience made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2498 holding.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.